Real-time monitoring assays of cell growth over 3 weeks indicated that NR2F1-overexpressing cells responded better to the triple combination treatment (Figure 5B), suggesting a potential therapeutic strategy to target DTP melanoma cells. This evidence concerns the gene NR2F1 and melanoma.